Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw some unusual options trading on Thursday. Stock investors purchased 27,659 put options on the stock. This represents an increase of 168% compared to the typical volume of 10,336 put options.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent research reports. Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday, July 17th. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analyst upgrade supports the rally. Teva’s shares rose 8.2% following an analyst upgrade, indicating improved confidence in the company’s earnings outlook and branded-drug strategy. Teva Pharmaceutical Industries Stock Price Up 8.2% Following Analyst Upgrade
• Positive Sentiment: Higher outlook and branded-product momentum lifted sentiment. Teva raised the midpoint of its 2026 revenue guidance by $75 million, while targeting AUSTEDO revenue of $2.45 billion-$2.6 billion and AJOVY revenue of $850 million-$870 million. Management said growth across the portfolio is helping offset pressure in its established generic-drug business. Teva Lifts Sales View as Brand-Name Business Gains Traction
• Positive Sentiment: UZEDY delivered record sales. Strong quarterly demand for the long-acting schizophrenia treatment prompted Teva to raise its 2026 UZEDY revenue outlook. Regulatory progress for a once-monthly olanzapine injection and a Tourette syndrome candidate also reinforced the company’s pipeline narrative. Teva Lifts UZEDY Outlook After Record Sales and New FDA Progress
• Neutral Sentiment: Revenue exceeded expectations, but profitability did not. Second-quarter revenue was approximately $4.14 billion and benefited from innovative medicines, but earnings missed estimates. Teva reported a $576 million net loss, largely reflecting Emalex acquisition-related costs and impairment charges, making the quality and sustainability of reported earnings an investor concern. Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
• Negative Sentiment: Heavy put-option activity signals hedging or bearish speculation. Investors acquired 27,659 put options, roughly 168% above typical volume. This does not prove a decline is imminent, but it suggests increased demand for downside protection after the stock’s strong recent run.

Teva Pharmaceutical Industries Trading Down 1.0%

Shares of Teva Pharmaceutical Industries stock opened at $35.05 on Friday. The firm has a market cap of $40.30 billion, a price-to-earnings ratio of 58.41, a price-to-earnings-growth ratio of 3.74 and a beta of 0.86. Teva Pharmaceutical Industries has a 52-week low of $14.99 and a 52-week high of $37.35. The company’s 50-day simple moving average is $33.24 and its 200-day simple moving average is $32.73. The company has a quick ratio of 0.78, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion during the quarter. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 300,493 shares of company stock worth $10,537,510 in the last three months. 0.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $25,000. Cornerstone Planning Group LLC raised its holdings in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock worth $42,000 after purchasing an additional 1,134 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.